AR036347A1 - Compuestos heterociclicos con actividades hipolipidemicas e hipocolesterolemicas, el proceso para su preparacion,las composiciones farmaceuticas que los contienen y su uso en medicina. - Google Patents
Compuestos heterociclicos con actividades hipolipidemicas e hipocolesterolemicas, el proceso para su preparacion,las composiciones farmaceuticas que los contienen y su uso en medicina.Info
- Publication number
- AR036347A1 AR036347A1 ARP020102839A ARP020102839A AR036347A1 AR 036347 A1 AR036347 A1 AR 036347A1 AR P020102839 A ARP020102839 A AR P020102839A AR P020102839 A ARP020102839 A AR P020102839A AR 036347 A1 AR036347 A1 AR 036347A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- alkylaminoinokylamino
- unsubstituted
- aralkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000000055 hyoplipidemic effect Effects 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 perhaloalkoxy Chemical group 0.000 abstract 9
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 4
- 125000002252 acyl group Chemical group 0.000 abstract 3
- 125000004183 alkoxy alkyl group Chemical class 0.000 abstract 3
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 3
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 abstract 2
- 125000005160 aryl oxy alkyl group Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000033 alkoxyamino group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 abstract 1
- 125000004949 alkyl amino carbonyl amino group Chemical group 0.000 abstract 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 1
- 125000005276 alkyl hydrazino group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 abstract 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 abstract 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 125000005162 aryl oxy carbonyl amino group Chemical group 0.000 abstract 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 abstract 1
- 125000005110 aryl thio group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 150000001602 bicycloalkyls Chemical group 0.000 abstract 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000000871 hypocholesterolemic effect Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F3/00—Input arrangements for transferring data to be processed into a form capable of being handled by the computer; Output arrangements for transferring data from processing unit to output unit, e.g. interface arrangements
- G06F3/14—Digital output to display device ; Cooperation and interconnection of the display device with other functional units
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
- G09G5/00—Control arrangements or circuits for visual indicators common to cathode-ray tube indicators and other visual indicators
- G09G5/36—Control arrangements or circuits for visual indicators common to cathode-ray tube indicators and other visual indicators characterised by the display of a graphic pattern, e.g. using an all-points-addressable [APA] memory
- G09G5/363—Graphics controllers
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F3/00—Input arrangements for transferring data to be processed into a form capable of being handled by the computer; Output arrangements for transferring data from processing unit to output unit, e.g. interface arrangements
- G06F3/14—Digital output to display device ; Cooperation and interconnection of the display device with other functional units
- G06F3/1423—Digital output to display device ; Cooperation and interconnection of the display device with other functional units controlling a plurality of local displays, e.g. CRT and flat panel display
- G06F3/1438—Digital output to display device ; Cooperation and interconnection of the display device with other functional units controlling a plurality of local displays, e.g. CRT and flat panel display using more than one graphics controller
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
- G09G2360/00—Aspects of the architecture of display systems
- G09G2360/12—Frame memory handling
- G09G2360/122—Tiling
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Theoretical Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- General Physics & Mathematics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Computer Graphics (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Human Computer Interaction (AREA)
- Endocrinology (AREA)
- Computer Hardware Design (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
Abstract
Compuestos heterocíclicos con actividades hipolipidémicas e hipocolesterolémicas de fórmula (1) en donde sus derivados, sus análogos, sus formas tautoméricas, sus estereoisómeros, sus polimorfos, sus sales farmacéuticamente aceptables, sus solvatos farmacéuticamente aceptables, en donde: R1, R2, R3 y R4 pueden ser iguales o diferentes y representar hidrógeno, halógeno, haloalquilo, perhaloalquilo, haloalcoxi, perhaloalcoxi, hidroxi, tio, amino, nitro, ciano, formilo, amidino, guanidino o grupos sustituidos o no sustituidos seleccionados de alquilo C1-12 lineal o ramificado, alquenilo C1-12 lineal o ramificado, alquinilo C1-12 lineal o ramificado, cicloalquilo C3-7, cicloalquenilo C3-7, bicicloalquilo, bicicloalquenilo, alcoxi C1-12, alquenoxi C1-12, cicloalcoxi C3-7, arilo, ariloxi, aralquilo, aralcoxi C1-12, heterociclilo, heteroarilo, heterociclilo-alquilo C1-12, heteroaralquilo C1-12, heteroariloxi, heteroaralcoxi C1-12, heterocicloxi, heterociclilalquiloxi, acilo, aciloxi, acilamino, amino monosustituido o di-sustituido, arilamino, aralquilamino, ácido carboxílico y sus derivados tales como ésteres y amidas, hidroxialquilo, aminoalquilo; aminoalquilo mono-sustituido o di-sustituido, alcoxialquilo, ariloxialquilo, aralcoxialquilo, alquiltio C1-12, tio-alquilo C1-12, ariltio, alcoxicarbonilamino C1-12, ariloxicarbonilamino, aralquiloxicarbonilamino, aminocarbonilamino, alquilaminocarbonilamino, alquilamidino, alquilguanidino, dialquilguanidino, hidracino, alquil hidracino, alcoxiamino, hidroxil amino, derivados de los grupos sulfenilo y sulfonilo, ácido sulfónico y sus derivados, ácido fosfónico y sus derivados; n representa un número entero que varía entre 1 y 8; W representa O, S o NR9, en donde R9 representa hidrógeno, grupos alquilo C1-12 o arilo; Ar representa un grupo aromático, heteroaromático o heterocíclico divalente simple o fusionado, y sustituido o no sustituido; R5 y R6 representan ambos hidrógeno o juntos representan un enlace o pueden también representar un grupo hidroxi, alquilo C1-12, alcoxi C1-12, halógeno, acilo, aralquilo sustituido o no sustituido; X representa O ó S; R7 representa hidrógeno, perfluoroalquilo C1-12, grupos sustituidos o no sustituidos seleccionados de alquilo C1-12, cicloalquilo C1-12, arilo, aralquilo C1-12, heteroarilo, heteroaralquilo C1-12, heterociclilo, alcoxialquilo, ariloxialquilo, alcoxicarbonilo, ariloxicarbonilo, cicloalquiloxicarbonilo, alquilaminocarbonilo, arilaminocarbonilo, o acilo lineales o ramificados; Y representa O ó S; Z representa O, S ó NR10, en donde R10 representa hidrógeno o grupos sustituidos o no sustituidos seleccionados de grupos alquilo C1-12, arilo, aralquilo C1-12, hidroxi-alquilo C1-12, amino-alquilo C1-12, heteroarilo o heteroaralquilo C1-12; R8 representa hidrógeno, grupos sustituidos o no sustituidos seleccionados de grupos alquilo C1-12, arilo, aralquilo C1-12, heteroarilo, heteroaralquilo C1-12, heterociclilo, heterociclilalquilo, hidroxialquilo, alcoxialquilo o alquilaminoalquilo lineales o ramificados; R10 y R8 juntos pueden formar una estructura de anillo heterocíclico sustituida o no sustituida, de 5 ó 6 miembros, con uno o más heteroátomos seleccionados de O, N ó S. La presente también está relacionada al proceso para la preparación de tales compuestos, una composición que contiene tal compuesto, y el uso de tal compuesto y composición en medicina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN711MU2001 | 2001-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR036347A1 true AR036347A1 (es) | 2004-09-01 |
Family
ID=11097270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020102839A AR036347A1 (es) | 2001-07-26 | 2002-07-26 | Compuestos heterociclicos con actividades hipolipidemicas e hipocolesterolemicas, el proceso para su preparacion,las composiciones farmaceuticas que los contienen y su uso en medicina. |
Country Status (31)
Country | Link |
---|---|
US (6) | US6987123B2 (es) |
EP (1) | EP1414439B1 (es) |
JP (2) | JP4313194B2 (es) |
KR (2) | KR100667710B1 (es) |
CN (1) | CN100450477C (es) |
AP (1) | AP1808A (es) |
AR (1) | AR036347A1 (es) |
AT (1) | ATE507828T1 (es) |
AU (1) | AU2002355205B2 (es) |
BR (1) | BRPI0211665B8 (es) |
CA (1) | CA2454863C (es) |
CO (1) | CO5390079A1 (es) |
CY (1) | CY1111876T1 (es) |
DE (1) | DE60239939D1 (es) |
DK (1) | DK1414439T3 (es) |
EA (1) | EA006858B1 (es) |
ES (1) | ES2366279T3 (es) |
HR (1) | HRP20040138B1 (es) |
IL (1) | IL160042A (es) |
MX (1) | MXPA04000758A (es) |
MY (1) | MY140057A (es) |
NO (1) | NO326698B1 (es) |
NZ (2) | NZ550375A (es) |
OA (1) | OA12702A (es) |
PL (1) | PL224397B1 (es) |
PT (1) | PT1414439E (es) |
RS (1) | RS51837B (es) |
SI (1) | SI1414439T1 (es) |
UA (1) | UA76992C2 (es) |
WO (1) | WO2003009841A1 (es) |
ZA (1) | ZA200400563B (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6987123B2 (en) * | 2001-07-26 | 2006-01-17 | Cadila Healthcare Limited | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine |
WO2003105864A1 (en) * | 2002-06-13 | 2003-12-24 | Board Of Regents, The University Of Texas System | Methods and compositions involving aldose reductase inhibitors |
US20050288373A1 (en) * | 2002-10-24 | 2005-12-29 | Ron Eyal S | Methods of treating various conditions by administration of sustained release L-arginine |
US20040248972A1 (en) * | 2003-05-16 | 2004-12-09 | Ambit Biosciences Corporation | Compounds and uses thereof |
US20050182125A1 (en) * | 2003-05-16 | 2005-08-18 | Ambit Biosciences Corporation | Pyrrole compounds and uses thereof |
JP2007500219A (ja) * | 2003-05-16 | 2007-01-11 | アンビット バイオサイエンシス コーポレーション | 複素環化合物およびその使用法 |
US9518899B2 (en) * | 2003-08-11 | 2016-12-13 | Sakura Finetek U.S.A., Inc. | Automated reagent dispensing system and method of operation |
US7744817B2 (en) * | 2003-08-11 | 2010-06-29 | Sakura Finetek U.S.A., Inc. | Manifold assembly |
US7767152B2 (en) * | 2003-08-11 | 2010-08-03 | Sakura Finetek U.S.A., Inc. | Reagent container and slide reaction retaining tray, and method of operation |
HUE041596T2 (hu) * | 2004-07-30 | 2019-05-28 | Exelixis Inc | Pirrol származékok mint gyógyászati szerek |
US20110092566A1 (en) * | 2004-11-19 | 2011-04-21 | Srivastava Satish K | Treatment of cancer with aldose reductase inhibitors |
CN103554095A (zh) * | 2006-02-15 | 2014-02-05 | Abbvie公司 | 新的乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 |
JP2009526868A (ja) | 2006-02-15 | 2009-07-23 | アボット・ラボラトリーズ | 新規なアセチル−CoAカルボキシラーゼ(ACC)阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用 |
US8459509B2 (en) * | 2006-05-25 | 2013-06-11 | Sakura Finetek U.S.A., Inc. | Fluid dispensing apparatus |
EP2848252A3 (en) | 2007-03-23 | 2015-06-17 | The Board of Regents of the University of Texas System | Aldose reductase inhibitors for use in treating uveitis |
US20090270490A1 (en) * | 2008-04-24 | 2009-10-29 | The Board Of Regents Of The University Of Texas System | Methods involving aldose reductase inhibition |
MX354133B (es) | 2010-08-18 | 2018-02-14 | Samumed Llc | Dicetonas e hidroxicetonas como activadores de la trayectoria de señalizacion de catenina. |
AU2015258299B2 (en) * | 2010-08-18 | 2017-10-19 | Samumed, Llc | Diketones and hydroxyketones as catenin signaling pathway activators |
AU2015268725B2 (en) * | 2011-01-31 | 2016-10-20 | Zydus Lifesciences Limited | Treatment for lipodystrophy |
CN107056671A (zh) * | 2011-01-31 | 2017-08-18 | 卡迪拉保健有限公司 | 脂肪代谢障碍的治疗 |
US8752732B2 (en) | 2011-02-01 | 2014-06-17 | Sakura Finetek U.S.A., Inc. | Fluid dispensing system |
JP5971657B2 (ja) * | 2011-04-20 | 2016-08-17 | 塩野義製薬株式会社 | Trpv4阻害活性を有する芳香族複素環誘導体 |
US8932543B2 (en) | 2011-09-21 | 2015-01-13 | Sakura Finetek U.S.A., Inc. | Automated staining system and reaction chamber |
US8580568B2 (en) | 2011-09-21 | 2013-11-12 | Sakura Finetek U.S.A., Inc. | Traceability for automated staining system |
US8754084B2 (en) | 2012-03-27 | 2014-06-17 | The Board Of Trustees Of The University Of Illinois | Therapeutic methods and agents for treating myotonic dystrophy |
LT2968249T (lt) | 2013-02-22 | 2019-03-12 | Samumed, Llc | Gama-diketonai, kaip wnt/beta-katenino signalinio kelio aktyvikliai |
EA201592020A1 (ru) * | 2013-04-22 | 2016-05-31 | Кадила Хелзкэр Лимитед | Новая композиция для неалкогольной жировой болезни печени (нажбп) |
EP3004053B1 (en) | 2013-05-30 | 2021-03-24 | Cadila Healthcare Limited | A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities |
TW201636015A (zh) * | 2013-07-05 | 2016-10-16 | 卡地拉保健有限公司 | 協同性組成物 |
IN2013MU02470A (es) | 2013-07-25 | 2015-06-26 | Cadila Healthcare Ltd | |
IN2013MU02828A (es) | 2013-08-29 | 2015-07-03 | Cadila Healthcare Ltd | |
IN2013MU02905A (es) | 2013-09-06 | 2015-07-03 | Cadila Healthcare Ltd | |
CA2956464C (en) | 2014-08-08 | 2023-05-09 | The Board Of Trustees Of The University Of Illinois | Bisamidinium-based inhibitors for the treatment of myotonic dystrophy |
RU2727039C2 (ru) | 2014-08-20 | 2020-07-17 | СЭМЬЮМЕД, ЭлЭлСи | Гамма-дикетоны для лечения и профилактики старения кожи и морщин |
WO2017064635A2 (en) | 2015-10-14 | 2017-04-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
WO2017089979A1 (en) | 2015-11-26 | 2017-06-01 | Cadila Healthcare Limited | Dual ppar modulators for the treatment of diabetic nephropathy and related diseases |
WO2017089980A1 (en) | 2015-11-26 | 2017-06-01 | Cadila Healthcare Limited | Dual ppar modulators for the treatment of diabetic retinopathy and diabetic eye diseases |
US20180243263A1 (en) | 2016-12-09 | 2018-08-30 | Cadila Healthcare Ltd. | Treatment for primary biliary cholangitis |
US11242326B2 (en) | 2017-08-25 | 2022-02-08 | The Board Of Trustees Of The University Of Illinois | Multivalent ligand for myotonic dystrophy |
US20220071954A1 (en) | 2018-12-18 | 2022-03-10 | Cadila Healthcare Limited | Saroglitazar for the treatment of hepatocellular carcinoma |
CN110372677B (zh) * | 2019-07-25 | 2021-01-05 | 浙江海森药业股份有限公司 | 一种无溶剂法制备阿托伐他汀关键中间体l1的方法 |
WO2021220236A1 (en) * | 2020-05-01 | 2021-11-04 | Cadila Healthcare Limited | Pharmaceutical compositions for combination therapy |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5089514A (en) | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
US6048883A (en) | 1992-07-03 | 2000-04-11 | Smithkline Beecham P.L.C. | Heterocyclic compounds as pharmaceutical |
GB9225386D0 (en) | 1992-12-04 | 1993-01-27 | Smithkline Beecham Plc | Novel compounds |
GB9311644D0 (en) | 1993-06-05 | 1993-07-21 | Smithkline Beecham Plc | Novel compounds |
US5387613A (en) | 1993-07-23 | 1995-02-07 | Ribogene, Inc. | Treatment of tachyarrhythmias of supraventricular origin |
GB9326171D0 (en) | 1993-12-22 | 1994-02-23 | Smithkline Beecham Plc | Novel compounds |
WO1996004261A1 (en) | 1994-07-29 | 1996-02-15 | Smithkline Beecham Plc | Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes |
US6075140A (en) | 1995-04-28 | 2000-06-13 | Daiichi Pharmaceutical Co., Ltd. | Pentacyclic compound |
NZ286920A (en) | 1995-07-03 | 1997-06-24 | Sankyo Co | Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma |
JP3220373B2 (ja) | 1995-11-28 | 2001-10-22 | バイエル薬品株式会社 | 持続性ニフエジピン製剤 |
GB9600464D0 (en) | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
DE19607953A1 (de) | 1996-03-01 | 1997-09-04 | Kalle Nalo Gmbh | Nach dem Aminoxidverfahren hergestellte Nahrungsmittelhüllen auf Cellulosebasis |
GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
US5889025A (en) | 1996-05-06 | 1999-03-30 | Reddy's Research Foundation | Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
ZA973848B (en) | 1996-05-06 | 1997-12-02 | Reddy Research Foundation | Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them. |
US5885997A (en) | 1996-07-01 | 1999-03-23 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
KR100579765B1 (ko) * | 1996-07-01 | 2006-12-28 | 닥터 레디스 레보러터리즈 리미티드 | 신규헤테로고리형화합물의제조방법,이를함유하는약제조성물및당뇨병및이와관련된질병의치료에있어서그의용도 |
EP0921798A1 (en) | 1996-07-12 | 1999-06-16 | Smithkline Beecham Plc | Novel treatment of leptine resistance |
WO1998028534A1 (en) | 1996-12-24 | 1998-07-02 | Daewoo Motor Co., Ltd. | An apparatus of exhaust gas recirculation valve for an internal combustion engine |
US6011036A (en) | 1997-04-15 | 2000-01-04 | Dr. Reddy's Research Foundation | Heterocyclic compounds having antidiabetic hypolipidemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them |
US6011031A (en) | 1997-05-30 | 2000-01-04 | Dr. Reddy's Research Foundation | Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them |
CZ273997A3 (cs) | 1997-09-02 | 1999-02-17 | Rieter Elitex A.S. | Spřádací ústrojí rotorového dopřádacího stroje |
HU228986B1 (en) * | 1997-09-11 | 2013-07-29 | Upjohn Co | Process to produce 4-hydroxy-2-oxo-pyrane derivatives useful as protease inhibitors |
ES2200248T3 (es) | 1997-09-19 | 2004-03-01 | Ssp Co., Ltd. | Derivados de acudi fenilpropionico sustituido en alfa y medicamento que los contienen. |
CN1280574A (zh) * | 1997-10-27 | 2001-01-17 | 雷迪研究基金会 | 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物 |
PL193086B1 (pl) * | 1997-10-27 | 2007-01-31 | Reddys Lab Ltd Dr | Nowe związki tricykliczne i związki pośrednie, sposób ich wytwarzania, zawierające je kompozycje farmaceutyczne oraz ich zastosowanie |
US6265401B1 (en) | 1997-10-27 | 2001-07-24 | Reddy-Cheminor, Inc. | Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
US6440961B1 (en) | 1997-10-27 | 2002-08-27 | Dr. Reddy's Research Foundation | Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
US6444816B1 (en) | 1997-10-27 | 2002-09-03 | Dr. Reddy's Research Foundation | Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof |
US6369067B1 (en) | 1997-10-27 | 2002-04-09 | Dr. Reddy's Research Foundation | Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
WO1999019313A1 (en) | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
WO1999038850A1 (en) | 1998-01-29 | 1999-08-05 | Dr. Reddy's Research Foundation | Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
EP1073643B1 (en) | 1998-04-23 | 2004-12-29 | Dr. Reddy's Laboratories Ltd. | New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
EP1082114B1 (en) | 1998-05-05 | 2002-08-28 | Sepracor, Inc. | Hydroxyomeprazole compositions and uses |
PL341795A1 (en) | 1998-05-27 | 2001-05-07 | Reddy Research Foundation | Bicycle compounds, process for obtaining them and pharmacological compositions containing such compounds |
SE9801990D0 (sv) | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl propionic acid derivatives and analogs |
US6589969B1 (en) | 1998-10-16 | 2003-07-08 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
WO2000023417A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
US6248781B1 (en) | 1998-10-21 | 2001-06-19 | Novo Nordisk A/S | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) |
JP2002527516A (ja) | 1998-10-21 | 2002-08-27 | ノボ ノルディスク アクティーゼルスカブ | 新規化合物、それらの製造及び使用 |
JP2002527520A (ja) | 1998-10-21 | 2002-08-27 | ノボ ノルディスク アクティーゼルスカブ | 新規化合物、その製造及び使用 |
WO2001005769A2 (en) | 1999-07-20 | 2001-01-25 | Dow Agrosciences Llc | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
US6312113B1 (en) * | 1999-10-29 | 2001-11-06 | Marconi Data Systems Inc. | Ink circulation system |
NZ520402A (en) * | 2000-01-19 | 2006-04-28 | Cadila Healthcare Ltd | Novel compounds having hypolipedemic, hypocholesteremic activites, process for their preparation and pharmaceutical compositions containing them |
US6569901B2 (en) | 2000-01-28 | 2003-05-27 | Novo Nordisk A/S | Alkynyl-substituted propionic acid derivatives, their preparation and use |
AU2001277056B2 (en) | 2000-07-25 | 2005-09-29 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
US6987123B2 (en) | 2001-07-26 | 2006-01-17 | Cadila Healthcare Limited | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine |
-
2001
- 2001-08-10 US US09/928,242 patent/US6987123B2/en not_active Expired - Lifetime
-
2002
- 2002-07-19 US US10/200,107 patent/US7041837B2/en not_active Expired - Lifetime
- 2002-07-25 EP EP02751609A patent/EP1414439B1/en not_active Expired - Lifetime
- 2002-07-25 PL PL368289A patent/PL224397B1/pl unknown
- 2002-07-25 MY MYPI20022774A patent/MY140057A/en unknown
- 2002-07-25 IL IL160042A patent/IL160042A/en not_active IP Right Cessation
- 2002-07-25 CO CO02064455A patent/CO5390079A1/es active IP Right Grant
- 2002-07-25 DE DE60239939T patent/DE60239939D1/de not_active Expired - Lifetime
- 2002-07-25 AP APAP/P/2004/002973A patent/AP1808A/en active
- 2002-07-25 OA OA1200400020A patent/OA12702A/en unknown
- 2002-07-25 CA CA2454863A patent/CA2454863C/en not_active Expired - Fee Related
- 2002-07-25 AT AT02751609T patent/ATE507828T1/de active
- 2002-07-25 NZ NZ550375A patent/NZ550375A/en not_active IP Right Cessation
- 2002-07-25 AU AU2002355205A patent/AU2002355205B2/en not_active Ceased
- 2002-07-25 JP JP2003515234A patent/JP4313194B2/ja not_active Expired - Fee Related
- 2002-07-25 KR KR1020047001174A patent/KR100667710B1/ko active IP Right Grant
- 2002-07-25 EA EA200400226A patent/EA006858B1/ru not_active IP Right Cessation
- 2002-07-25 US US10/592,880 patent/US8212057B2/en active Active
- 2002-07-25 DK DK02751609.5T patent/DK1414439T3/da active
- 2002-07-25 NZ NZ545896A patent/NZ545896A/en not_active IP Right Cessation
- 2002-07-25 MX MXPA04000758A patent/MXPA04000758A/es active IP Right Grant
- 2002-07-25 SI SI200230947T patent/SI1414439T1/sl unknown
- 2002-07-25 PT PT02751609T patent/PT1414439E/pt unknown
- 2002-07-25 KR KR1020067015951A patent/KR20060094545A/ko not_active Application Discontinuation
- 2002-07-25 UA UA2004021090A patent/UA76992C2/uk unknown
- 2002-07-25 ES ES02751609T patent/ES2366279T3/es not_active Expired - Lifetime
- 2002-07-25 RS YU17404A patent/RS51837B/sr unknown
- 2002-07-25 BR BRPI0211665A patent/BRPI0211665B8/pt not_active IP Right Cessation
- 2002-07-25 CN CNB028189833A patent/CN100450477C/zh not_active Expired - Fee Related
- 2002-07-25 WO PCT/IN2002/000155 patent/WO2003009841A1/en active Application Filing
- 2002-07-26 AR ARP020102839A patent/AR036347A1/es active IP Right Grant
-
2004
- 2004-01-23 NO NO20040301A patent/NO326698B1/no not_active IP Right Cessation
- 2004-01-26 ZA ZA200400563A patent/ZA200400563B/en unknown
- 2004-02-12 HR HRP20040138AA patent/HRP20040138B1/hr not_active IP Right Cessation
- 2004-03-01 US US10/790,647 patent/US7323491B2/en not_active Expired - Lifetime
-
2008
- 2008-01-23 US US12/018,555 patent/US8110598B2/en not_active Expired - Fee Related
-
2009
- 2009-02-04 JP JP2009024338A patent/JP2009102423A/ja active Pending
-
2011
- 2011-04-25 US US13/066,807 patent/US8558009B2/en not_active Expired - Lifetime
- 2011-07-20 CY CY20111100708T patent/CY1111876T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR036347A1 (es) | Compuestos heterociclicos con actividades hipolipidemicas e hipocolesterolemicas, el proceso para su preparacion,las composiciones farmaceuticas que los contienen y su uso en medicina. | |
ES2618630T3 (es) | Composiciones terapéuticas y métodos de uso relacionados | |
MX2009003410A (es) | Fosfoindoles enantiomericamente puros como inhibidores de vih. | |
AR032626A1 (es) | Amidas, composiciones farmaceuticas que las comprenden, proceso para preparar dichas composiciones, uso de dichas amidas en la preparacion de medicamentos, y proceso para la preparacion de dichas amidas | |
CY1105035T1 (el) | Συγχωνευμενα με αρυλιο ή ετεροαρυλιο παραγωγα της ιμιδαζολης ως αντιφλεγμονωδεις και αναλγητικοι παραγοντες | |
AR046244A1 (es) | Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos | |
AR060991A1 (es) | Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilo y composiciones farmaceuticas que los contienen utilizadas para el tratamiento de la diabetes | |
ES2655091T3 (es) | Derivados del ácido pirrolidíncarboxílico como agonistas del receptor 43 acoplado a proteína G (GPR43), composición farmacéutica y métodos para su uso en el tratamiento de trastornos metabólicos | |
UY26727A1 (es) | Derivados de tropano útiles en terapia | |
AR033836A1 (es) | Compuesto 2-anilino-(imidazol-5-il)-pirimidina, composicion farmaceutica que lo comprende, su uso en la fabricacion de un medicamento que produce un efecto inhibitorio del ciclo celular y un proceso para su preparacion | |
CO5700824A2 (es) | Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen | |
CO6220931A2 (es) | Inhibidores de serina proteasas para el tratamiento de infecciones de vhc | |
AR011101A1 (es) | Compuesto derivado de acidos arilsulfonilaminohidroxiamicos y composicion farmaceutica que lo contiene | |
AR071043A1 (es) | Acido l -glutamico marcado con (f -18), l- glutamina marcada con (f-18), sus derivados y su uso, asi como procedimientos para su preparacion | |
AR035777A1 (es) | Derivados de pirazol sustituidos, procesos para su preparacion, composiciones farmaceuticas que los contienen, y su uso en medicina | |
AR054484A1 (es) | Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol | |
PA8795301A1 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
ES2119325T3 (es) | Compuestos polienicos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones. | |
CO5690551A2 (es) | Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo | |
AR039927A1 (es) | Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen | |
ES2180995T3 (es) | Nuevos derivados de tiazolidina-2,4-diona substituidos, sus procedimientos de obtencion y las composiciones farmaceuticas que los contienen. | |
AR045159A1 (es) | Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos | |
PE20212323A1 (es) | Formulaciones farmaceuticas | |
PE20090548A1 (es) | Compuestos aza-biciclohexano como inhibidores de trombina | |
PE20220252A1 (es) | Compuestos de pirrol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |